Quick Answer
BriaCell Therapeutics Corp. reported Operating Income of -$27.20 million for fiscal year 2025.
BriaCell Therapeutics Corp. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$27.20M | +18.4% |
| 2024 | -$33.33M | -43.2% |
| 2023 | -$23.27M | -52.2% |
| 2022 | -$15.29M | -119.2% |
| 2021 | -$6.98M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| October 31, 2025 | -$8.32M | -61.5% | -31.5% |
| April 30, 2025 | -$6.33M | +31.4% | +11.7% |
| January 31, 2025 | -$7.17M | +27.1% | -39.1% |
| October 31, 2024 | -$5.15M | +39.4% | +44.2% |
| April 30, 2024 | -$9.23M | -62.6% | +6.1% |
| January 31, 2024 | -$9.83M | -119.1% | -15.6% |
| October 31, 2023 | -$8.50M | -57.4% | -49.8% |
| April 30, 2023 | -$5.68M | -37.7% | -26.5% |
- BriaCell Therapeutics Corp. showed an increase of +18.4% in Operating Income compared to the prior fiscal year.
- Over the 2021–2025 period, BriaCell Therapeutics Corp.’s operating income has declined by 290.0% (from -$6.98 million to -$27.20 million).
- The most recent figure is from BriaCell Therapeutics Corp.’s fiscal year 2025 report (Form 10-K), filed with the SEC on October 16, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: